Skip to main content

Table 2 Adverse events

From: Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy

Adverse events. No. (%)

All grades (1–4)

Grade 3

Grade 4

GEMOX

Gem/Carb

GEMOX

Gem/Carb

GEMOX

Gem/Carb

(n = 44)

(n = 20)

(n = 44)

(n = 20)

(n = 44)

(n = 20)

Haematological

      

Anaemia

19 (43)

15 (75)

1 (2)

8 (40)

0

1 (5)

Thrombocytopenia

16 (36)

12 (60)

1 (2)

6 (30)

0

3 (15)

Neutropenia

4 (9)

10 (50)

0

6 (30)

1 (2)

2 (10)

Febrile neutropenia

1 (2)

0

0

0

0

0

Non haematological

      

Fatigue

14 (32)

4 (20)

0

2 (10)

0

0

Nausea

10 (23)

3 (15)

0

2 (10)

0

0

Vomiting

6 (14)

4 (20)

0

3 (15)

0

0

Liver toxicity

3 (7)

2 (10)

0

0

0

0

Peripheral neuropathy

26 (59)

0

3 (7)

0

0

0

Infection without neutropenia

9 (21)

1 (5)

0

1 (5)

0

0

Renal toxicity

2 (5)

0

0

0

0

0

  1. Abbreviations: GEMOX gemcitabine and oxaliplatine combination regimen, Gem/Carb gemcitabine and carboplatin combination regimen.